The effect of bupropion sustained-release on cigarette craving after smoking cessation

Michael J. Durcan, Greg Deener, Jonathan White, J. Andrew Johnston, David Gonzales, Raymond Niaura, Nancy Rigotti, David P.L. Sachs

Research output: Contribution to journalArticle

Abstract

Background: Most (>50%) smokers who attempt to stop smoking relapse within the first year of abstinence. The effect of continued use of pharmacotherapy for smoking cessation on relapse rates is unknown. Bupropion sustained-release (SR) is the first non-nicotine-based therapy that is effective for achieving abstinence from smoking. Objective: This analysis explored the factors involved in relapse to smoking in patients who had successfully stopped smoking using bupropion SR. These patients were participants in a double-blind, placebo-controlled trial of bupropion SR for the prevention of relapse to smoking. Methods: Participants who had stopped smoking with 7 weeks of open-label bupropion SR were randomly assigned to receive double-blind treatment with either bupropion SR or placebo for 45 weeks. The primary efficacy outcome of the main study was the rate of relapse to smoking. The analyses presented here examine the levels of reported cigarette craving and, in those participants who returned to smoking, the reasons associated with relapse, using patient-completed questionnaires. Results: Craving was cited most frequently as a factor contributing to relapse in those participants receiving placebo (cited by 49.2% of relapsers) but significantly less frequently by participants receiving bupropion SR (cited by 22.4% of relapsers) (P < 0.05). Results from patients' diaries showed no differences between bupropion SR and placebo in terms of "craving in the past 24 hours" but significantly lower scores for "craving right now" for bupropion SR at weeks 11 and 12 (P < 0.05). Results at scheduled visits showed that "craving in the past 24 hours" was significantly less with bupropion SR compared with placebo at weeks 12, 20, and 48, and "craving right now" was significantly less with bupropion SR compared with placebo at weeks 12, 16, 20, 24, 48, and 52 (P < 0.05). Conclusions: Craving continues to be a significant concern for individuals even after they have successfully stopped smoking. Bupropion SR appears to reduce reported cravings, which may contribute to the overall reduction in the rate of relapse observed with this pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)540-551
Number of pages12
JournalClinical Therapeutics
Volume24
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Bupropion
Smoking Cessation
Tobacco Products
Smoking
Recurrence
Placebos
Craving
Drug Therapy
Secondary Prevention
Statistical Factor Analysis
Outcome Assessment (Health Care)

Keywords

  • Bupropion sustained-release
  • Craving
  • Nicotine
  • Relapse prevention
  • Smoking cessation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Durcan, M. J., Deener, G., White, J., Johnston, J. A., Gonzales, D., Niaura, R., ... Sachs, D. P. L. (2002). The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clinical Therapeutics, 24(4), 540-551. https://doi.org/10.1016/S0149-2918(02)85130-X

The effect of bupropion sustained-release on cigarette craving after smoking cessation. / Durcan, Michael J.; Deener, Greg; White, Jonathan; Johnston, J. Andrew; Gonzales, David; Niaura, Raymond; Rigotti, Nancy; Sachs, David P.L.

In: Clinical Therapeutics, Vol. 24, No. 4, 2002, p. 540-551.

Research output: Contribution to journalArticle

Durcan, MJ, Deener, G, White, J, Johnston, JA, Gonzales, D, Niaura, R, Rigotti, N & Sachs, DPL 2002, 'The effect of bupropion sustained-release on cigarette craving after smoking cessation', Clinical Therapeutics, vol. 24, no. 4, pp. 540-551. https://doi.org/10.1016/S0149-2918(02)85130-X
Durcan, Michael J. ; Deener, Greg ; White, Jonathan ; Johnston, J. Andrew ; Gonzales, David ; Niaura, Raymond ; Rigotti, Nancy ; Sachs, David P.L. / The effect of bupropion sustained-release on cigarette craving after smoking cessation. In: Clinical Therapeutics. 2002 ; Vol. 24, No. 4. pp. 540-551.
@article{6d714456b95f4a649ba03b2f8fd076fa,
title = "The effect of bupropion sustained-release on cigarette craving after smoking cessation",
abstract = "Background: Most (>50{\%}) smokers who attempt to stop smoking relapse within the first year of abstinence. The effect of continued use of pharmacotherapy for smoking cessation on relapse rates is unknown. Bupropion sustained-release (SR) is the first non-nicotine-based therapy that is effective for achieving abstinence from smoking. Objective: This analysis explored the factors involved in relapse to smoking in patients who had successfully stopped smoking using bupropion SR. These patients were participants in a double-blind, placebo-controlled trial of bupropion SR for the prevention of relapse to smoking. Methods: Participants who had stopped smoking with 7 weeks of open-label bupropion SR were randomly assigned to receive double-blind treatment with either bupropion SR or placebo for 45 weeks. The primary efficacy outcome of the main study was the rate of relapse to smoking. The analyses presented here examine the levels of reported cigarette craving and, in those participants who returned to smoking, the reasons associated with relapse, using patient-completed questionnaires. Results: Craving was cited most frequently as a factor contributing to relapse in those participants receiving placebo (cited by 49.2{\%} of relapsers) but significantly less frequently by participants receiving bupropion SR (cited by 22.4{\%} of relapsers) (P < 0.05). Results from patients' diaries showed no differences between bupropion SR and placebo in terms of {"}craving in the past 24 hours{"} but significantly lower scores for {"}craving right now{"} for bupropion SR at weeks 11 and 12 (P < 0.05). Results at scheduled visits showed that {"}craving in the past 24 hours{"} was significantly less with bupropion SR compared with placebo at weeks 12, 20, and 48, and {"}craving right now{"} was significantly less with bupropion SR compared with placebo at weeks 12, 16, 20, 24, 48, and 52 (P < 0.05). Conclusions: Craving continues to be a significant concern for individuals even after they have successfully stopped smoking. Bupropion SR appears to reduce reported cravings, which may contribute to the overall reduction in the rate of relapse observed with this pharmacotherapy.",
keywords = "Bupropion sustained-release, Craving, Nicotine, Relapse prevention, Smoking cessation",
author = "Durcan, {Michael J.} and Greg Deener and Jonathan White and Johnston, {J. Andrew} and David Gonzales and Raymond Niaura and Nancy Rigotti and Sachs, {David P.L.}",
year = "2002",
doi = "10.1016/S0149-2918(02)85130-X",
language = "English (US)",
volume = "24",
pages = "540--551",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - The effect of bupropion sustained-release on cigarette craving after smoking cessation

AU - Durcan, Michael J.

AU - Deener, Greg

AU - White, Jonathan

AU - Johnston, J. Andrew

AU - Gonzales, David

AU - Niaura, Raymond

AU - Rigotti, Nancy

AU - Sachs, David P.L.

PY - 2002

Y1 - 2002

N2 - Background: Most (>50%) smokers who attempt to stop smoking relapse within the first year of abstinence. The effect of continued use of pharmacotherapy for smoking cessation on relapse rates is unknown. Bupropion sustained-release (SR) is the first non-nicotine-based therapy that is effective for achieving abstinence from smoking. Objective: This analysis explored the factors involved in relapse to smoking in patients who had successfully stopped smoking using bupropion SR. These patients were participants in a double-blind, placebo-controlled trial of bupropion SR for the prevention of relapse to smoking. Methods: Participants who had stopped smoking with 7 weeks of open-label bupropion SR were randomly assigned to receive double-blind treatment with either bupropion SR or placebo for 45 weeks. The primary efficacy outcome of the main study was the rate of relapse to smoking. The analyses presented here examine the levels of reported cigarette craving and, in those participants who returned to smoking, the reasons associated with relapse, using patient-completed questionnaires. Results: Craving was cited most frequently as a factor contributing to relapse in those participants receiving placebo (cited by 49.2% of relapsers) but significantly less frequently by participants receiving bupropion SR (cited by 22.4% of relapsers) (P < 0.05). Results from patients' diaries showed no differences between bupropion SR and placebo in terms of "craving in the past 24 hours" but significantly lower scores for "craving right now" for bupropion SR at weeks 11 and 12 (P < 0.05). Results at scheduled visits showed that "craving in the past 24 hours" was significantly less with bupropion SR compared with placebo at weeks 12, 20, and 48, and "craving right now" was significantly less with bupropion SR compared with placebo at weeks 12, 16, 20, 24, 48, and 52 (P < 0.05). Conclusions: Craving continues to be a significant concern for individuals even after they have successfully stopped smoking. Bupropion SR appears to reduce reported cravings, which may contribute to the overall reduction in the rate of relapse observed with this pharmacotherapy.

AB - Background: Most (>50%) smokers who attempt to stop smoking relapse within the first year of abstinence. The effect of continued use of pharmacotherapy for smoking cessation on relapse rates is unknown. Bupropion sustained-release (SR) is the first non-nicotine-based therapy that is effective for achieving abstinence from smoking. Objective: This analysis explored the factors involved in relapse to smoking in patients who had successfully stopped smoking using bupropion SR. These patients were participants in a double-blind, placebo-controlled trial of bupropion SR for the prevention of relapse to smoking. Methods: Participants who had stopped smoking with 7 weeks of open-label bupropion SR were randomly assigned to receive double-blind treatment with either bupropion SR or placebo for 45 weeks. The primary efficacy outcome of the main study was the rate of relapse to smoking. The analyses presented here examine the levels of reported cigarette craving and, in those participants who returned to smoking, the reasons associated with relapse, using patient-completed questionnaires. Results: Craving was cited most frequently as a factor contributing to relapse in those participants receiving placebo (cited by 49.2% of relapsers) but significantly less frequently by participants receiving bupropion SR (cited by 22.4% of relapsers) (P < 0.05). Results from patients' diaries showed no differences between bupropion SR and placebo in terms of "craving in the past 24 hours" but significantly lower scores for "craving right now" for bupropion SR at weeks 11 and 12 (P < 0.05). Results at scheduled visits showed that "craving in the past 24 hours" was significantly less with bupropion SR compared with placebo at weeks 12, 20, and 48, and "craving right now" was significantly less with bupropion SR compared with placebo at weeks 12, 16, 20, 24, 48, and 52 (P < 0.05). Conclusions: Craving continues to be a significant concern for individuals even after they have successfully stopped smoking. Bupropion SR appears to reduce reported cravings, which may contribute to the overall reduction in the rate of relapse observed with this pharmacotherapy.

KW - Bupropion sustained-release

KW - Craving

KW - Nicotine

KW - Relapse prevention

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=0036245460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036245460&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(02)85130-X

DO - 10.1016/S0149-2918(02)85130-X

M3 - Article

VL - 24

SP - 540

EP - 551

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -